Bacterial Keratitis Should optometrists treat in the community?

Similar documents
REVIEW OF OPHTHALMOLOGY SECTION OF WHO MODEL LIST OF ESSENTIAL MEDICINES. Sight Savers International and The Vision 2020 Technology Group

Role of Moxifloxacin in Bacterial Keratitis

Study of Bacteriological Profile of Corneal Ulcers in Patients Attending VIMS, Ballari, India

Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia

Topical Antibiotic Update. Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures

Evaluation of Moxifloxacin 0.5% Eye Drops in Treatment of Bacterial Corneal Ulcers

Submission for Reclassification

Author of PGD: Adrian MacKenzie, Lead Pharmacist, Community Pharmacy.

Financial disclosures

THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of NHS Fife by:

CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

Treatment of septic peritonitis

Debate Series editors: Susan Lightman and Peter McCluskey

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

INTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre

Please call the Pharmacy Medicines Unit on or for a copy.

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

Suitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)

Responsible use of antimicrobials in veterinary practice

PRESCRIBING INFORMATION

Global Status of Antimicrobial Resistance with a Focus on Nepal

ECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018

Dr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust

Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers

Dry Eye Keratoconjunctivitis sicca (KCS)

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

Let me clear my throat: empiric antibiotics in

Equine gastric squamous and glandular disease update

Unshakeable confidence

Antimicrobial Stewardship

JF Akinrinmade & OI Ogungbenro*

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

Critical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary

Effectiveness of doxycycline for lyme disease

Package leaflet: Information for the user. HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol

Considerations in antimicrobial prescribing Perspective: drug resistance

Index. Note: Page numbers of article titles are in boldface type.

International Journal of Research and Review E-ISSN: ; P-ISSN:

Antimicrobial Stewardship

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

Disclosure. Update on management of fungal keratitis. Acknowledgments. World Blindness 1993

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

Antibiotic Resistance

Delayed Prescribing for Minor Infections Resource Pack for Prescribers

PRODUCT INFORMATION CHLORSIG

Clinical Study Update: Surgical Therapeutics

Diagnosis: Presenting signs and Symptoms include:

Package leaflet: Information for the user. GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin

Is Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process?

In vitro antibiotic resistance in bacterial keratitis in London

MANAGEMENT OF PELVIC INFLAMMATORY DISEASE

ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET

Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Standing Orders for the Treatment of Outpatient Peritonitis

Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis

Infectious keratitis for the general ophthalmologist

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE

Antimicrobial Stewardship Strategy: Antibiograms

Rational management of community acquired infections

PACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children

Antibiotic courses and antibiotic conservation, getting the balance right

A patient s guide to. MRSA - Methicillin Resistant Staphylococcus Aureus

Principles of Antimicrobial therapy

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

SSTI s :A Guideline for Effective Treatment of Skin and Soft Tissue Infections

Standing Orders for the Treatment of Outpatient Peritonitis

A Current Look at Navicular Syndrome. Patrick First, DVM

Antimicrobial Stewardship in the Hospital Setting

Preventing and Responding to Antibiotic Resistant Infections in New Hampshire

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

Responsible use of antibiotics

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

Updates in Antimicrobial Stewardship

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

Class Update with New Drug Evaluation: Ototopical Antibiotics

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM

F1 IN THE NAME OF GOD

TREAT Steward. Antimicrobial Stewardship software with personalized decision support

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

PACK-CXL. for infectious keratitis. Farhad Hafezi, MD PhD. Professor of Ophthalmology Keck School of Medicine USC Los Angeles, USA

IDENTIFICATION: PROCESS: Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital

Author - Dr. Josie Traub-Dargatz

Feline lower urinary tract disease (FLUTD)

The active component of CHLOROMYCETIN eye ointment is chloramphenicol.

Prescribing Management

Cystic Fibrosis- management of Burkholderia. cepacia complex infections

Burn Infection & Laboratory Diagnosis

Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without

Transcription:

Case Record 13 Bacterial Keratitis Should optometrists treat in the community? December 2008 Dr Peter Frampton DOptom MSc FCOptom BAppSc(Optom)(AUS) DipTp(AS) DipTp(SP) DipTp(IP)

Introduction Can Optometrists Deal with Bacterial Keratitis? Ray-Chaudhuri (2005) states that suspect bacterial keratitis require a corneal scrape and culture. There are no exclusion criteria. Charukamnoetkanok and Pineda (2005) however, report yields as low as 63% from cultures and suggest that routine sensitivity testing rarely alters the treatment outcome. Morlet and Daniell (2003) indicate that over 80% of ulcers respond well to empirical broad-spectrum treatment. Regardless no clinician wants to face a worsening keratitis without the benefit of pathogen sensitivities. Would a more objective method of pre-assessing treatment efficacy be of value? Morlet and Daniell (2003) indicate that significant predictive factors for culture success or failure are lesion size, promptness of presentation, patient age, co-existing corneal pathology and use of topical steroids. A general reduction in immune competence would also contribute. Young patients with small ulcers should respond well with empirical treatment and would be unlikely to be culture positive. Conversely, the elderly (>60 years), with large ulcers (> 5mm) had 5.5 times the risk of primary treatment failure (Morlet and Daniell 2003). Vital, Belloso, Prager and Lanier (2007) amalgamated these observations in the objective 1,2,3 guidelines. O Brien (2003) further suggests that resistance is unlikely with community-acquired keratitis, leaving these micro-organisms more susceptible to off the shelf antibiotics. Green, Apel and Stapleton (2008) demonstrated that the majority of community-acquired ulcers were in younger, immuno-competent patients without co-existing pathology. Patients with ocular surface disease or undergoing ocular surgery were older and required more protracted treatment. However, individualised treatment decisions need to consider contemporaneous data regarding local micro-flora, information that cannot be collated without culturing (Ofloxacin Study Group 1997, Morlet and Daniell 2003). Further there is growing evidence of increasing resistance of a variety of organisms to many antibiotics, including the Quinolones (Bearden and Danziger 2001, Watanabe, Numata-Watanabe and Hayasaka 2001, Mills 2003, Charukamnoetkanok and Pineda 2005, Khosravi, Mehdine and Heidari 2007).

There will always be some clinical decisions based on assessed severity, symptoms, compliance and ease of access to laboratory facilities. Objective quantification of each presentation is very valuable but can t replace culturing, a skill optometrists need to acquire. This case does demonstrate that optometrists are ideally suited to triage presentations before inappropriate treatment is instigated. MK Day 1 Slit lamp examination revealed obvious diffuse stromal staining indicating a break in the basal lamina. No history of trauma was elicited and the lesion was diagnosed as bacterial keratitis. Whether infective or not, urgent management would be indicated, due to the stromal involvement (Fleiszig 2006). The patient reported being prescribed chloramphenicol the previous day, to little effect. Use of ineffective antibiotics can seriously reduce the chances of obtaining a positive culture. Immediate referral to Eye Casualty was arranged; the need for fortified antibiotics or an aminoglycoside was considered probable in light of the previous intervention. HES The prompt presentation, small lesion size and state of health of the patient and probable compromise of culture success prompted empirical treatment with Ofloxacin 0.3% q1h, after initial loading dose to achieve therapeutic titre, with Chloramphenicol ointment nocte and Cyclopentolate 1% tid. Ofloxacin is licensed for use against keratoconjunctivitis, however Chloramphenicol, bacteriostatic and ineffective against Pseudomonas aeruginosa, is only indicated for the treatment of acute bacterial conjunctivitis (emc 2008). The choice of Chloramphenicol ointment was for nocturnal cover. Ciprofloxaicin, available as both a drop and ointment and licensed for bacterial keratitis (emc 2008) would seem a better choice for nyctohemeral cover.

Inappropriate use of antibiotics falls into two categories, incorrect diagnosis and sub-therapeutic dosing (Charukamnoetkanok and Pineda 2005). To avoid the second hazard O Brien (2003) recommends an initial loading dose of one drop every two minutes for five applications. This initial corneal marinade approach was instigated, followed by q1h for the rest of the day. Outpatient management is appropriate for compliant patients with mild keratitis but necessitates meticulous follow-up (Onofrey et al 1998, O Brien 2003, Charukamnoetkanok and Pineda 2005). Day 2 : First Review O Brien (2003) comments that, even with effective bactericidal therapy, 48 to 72 hours can elapse before progression is halted. Improvement in signs and symptoms were evident. The reducing lesion size, coupled with reduced stromal staining, supported the view that the management was effective. The patient was referred back to community care for follow-up. Days 3 to 7 Resolution was closely monitored over a further five days. Early morning appointments were arranged to suit the patient s commitments and allow prompt re-referral to the HES if improvement was not noted. It is often easier to commence than to stop treatment (Morlet and Daniell 2003). End points of treatment are re-epithelialisaton and non-progression of stromal infiltrates (O Brien 2003). However, toxicity to the medication can mask epithelial heal (Morlet and Daniall 2003). While fluoroquinolones are less toxic than the aminoglycosides, effects can still manifest (Gwon for the OSG 1992) and be enhanced by overly prolonged initial intensive treatment (Morlet and Daniell 2003). These authors suggest that 48 hours of high concentrations is enough to eliminate most bacterial infections; reducing doses after this time. Vital et al (2007) modified frequency and duration of therapy on clinical response as epithelialization was observed.

Caution with cessation of therapy is advocated in case of corneal tissue persistent organisms, such as Pseudomonas aeruginosa (O Brien 2003). Continued prophylactic cover is indicated even after observable heal is achieved. The patient was only discharged after several days of prophlactic cover. Discussion and Adjunctive Therapy The aim of treatment should not simply be to eradicate the infective agent, but also to reduce the inflammatory response, prevent structural damage to the cornea and promote healing of the epithelial surface (O Brien 2003). Pain management must also be considered. The use of cycloplegics, as well as preventing formation of synechiae if anterior chamber inflammation is noted, relieves ciliary spasm and alleviates pain (O Brien 2003). Morlet and Daniell (2003) suggest that oral doxycycline, if the ulcer is large and exhibits corneal thinning, can be a beneficial adjunct to the topical medications. Patching is contraindicated in active infection (O Brien 2003). Simple palliatives to optimise the ocular surface environment, particularly non-preserved solutions with Sodium Hyaluronate (Condon, McEwan, Wright, Mackintosh, Prescott and McDonald 1999), have been demonstrated to encourage epithelial heal (Morlet and Daniell 2003). Corticosteroids can be used with caution once the pathogens have been eliminated (O Brien 2003). Ray-Chaudhuri (2005) considers a weak steroid appropriate after 48 hours of intense anti-bacterial therapy. These medications decrease the host inflammatory response but longer treatment courses and a higher likelihood of recurrence have been observed (O Brien 2003). Charukamnoetkanok and Pineda (2005) list guidelines for steroid use : 1) steroids should not be used initially, 2) they should not be used if the eye is improving, 3) they may be used after total sterilization if there is ongoing inflammation, 4) concomitant use of antibiotics must be maintained, 5) steroids should not be used in the presence of stromal thinning.

REFERENCES 1. Bearden D T and Danziger L H. (2001). Mechanisms of Action of and Resistance to Quinolones. Pharmacotherapy, 21 (10), 224-232. 2. Charukamnoetkanok P and Pineda R. (2005). Controversies in Management of Bacterial Keratitis. 199-210. 3. Condon P, McEwan C, Wright M, Mackintosh G, Prescott R and McDonald C. (1999). Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. British J Ophthalmology, 83 : 1121-1124. 4. Electronic Medicines Compendium. (2008). Medicines.org.uk. Accessed from : emc.medicines.org.uk 5. Fleiszig S. (2006). The Pathogenesis of Contact Lens-Related Keratitis. Optometry and Vision Science, 83(12) : 866-873. 6. Green M, Apel A and Stapleton F. (2008). Risk Factors and Causative Organisms in Microbial Keratitis. Cornea, 27(1) : 22-27. 7. Gwon A for the Ofloxacin Study Group. (1992). Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. British J of Ophthalmology, 76 : 714-718. 8. Khorsravi A, Mehdinejad M and Heidari M. (2007). Bacteriologic Findings in Patients with Ocular Infection and Antibiotic Susceptibility Patterns of Isolated Pathogens. Pak J Med Sci, 23(4) : 566-569. 9. Mills R. (2003). View 1 : Corneal scraping and combination antibiotic therapy is indicated. British J Ophthalmology, 87 : 1167-1169. 10. Morlet N and Daniell M. (2003). View 2 : Empirical fluoroquinolone therapy is sufficient initial treatment. British J Ophthalmology, 87 : 1169-1172

11. O Brien T. (2003). Management of Bacterial Keratitis : beyond exorcism and towards consideration of organism and host factors. Eye, 17 : 957-974. 12. Ofloxacin Study Group. (1997). Ofloxacin Monotherapy for the Primary Treatment of Microbial Keratitis : A Doublemasked, Randomized, Controlled Trial with Conventional Dual Therapy. Ophthalmology, 104(11) : 1902-1909. 13. Onofrey B E, Skorin L and Holdeman N R. (1998). Ocular Therapeutics Handbook, A clinical manual. Lippincott-Raven. USA. 14. Ray-Chaudhuri (Ed). (2005). Royal Victoria Infirmary Eye Casualty Guidelines. The Newcastle upon Tyne Hospitals NHS Trust. Access www.newcastle-hospitals.org.uk 15. Vital M, Belloso M, Prager T and Lanier J. (2007). Classifying the Severity of Corneal Ulcers by Using the 1,2,3 Rule. Cornea, 26(1) : 16-20. 16. Watanabe K, Numata-Watanabe and Hayasaka S. (2001). Methicillin-Resistant Staphylococci and Ofloxacin- Resistant Bacteria from Clinically Healthy Conjunctivas. Ophthalmic Research, 33 : 136-139.